What Is Fasting Glucose? Normal vs Optimal Range Explained

The lab cutoff of 100 mg/dL for "normal" fasting glucose creates a dangerous false reassurance. Metabolic dysfunction begins well before the prediabetes threshold—the Whitehall II study demonstrated that beta-cell function starts declining 10–12 years before a diabetes diagnosis, with fasting glucose creeping upward through the 90s for years before crossing 100. The CTD catalogs over 11,200 compound interactions with glucose metabolism genes, reflecting the staggering number of medications, toxins, and dietary compounds that influence blood sugar regulation. A fasting glucose of 95 mg/dL means your pancreas is likely producing significantly more insulin than optimal to hold glucose at that level. The optimal range of 75–85 mg/dL represents the zone where insulin sensitivity is highest and the pancreas operates with minimal strain—your metabolic reserve is intact rather than being slowly depleted.

PubMed indexes over 280,000 publications on fasting glucose, making it one of the most studied biomarkers in medicine. The critical insight that most lab reports miss: fasting glucose is the last domino to fall in metabolic dysfunction, not the first. Insulin resistance develops years before glucose rises because the pancreas compensates by producing more insulin. You can have a "perfect" fasting glucose of 92 mg/dL while your fasting insulin is 18 µIU/mL—indicating your pancreas is working three times harder than normal to maintain that glucose level. PharmGKB documents over 340 pharmacogenomic associations with glucose-regulating pathways, explaining why identical medications produce different glucose effects in different patients based on genetic variants in glucose transporter and insulin receptor genes.

FAERS documents over 85,000 adverse event reports involving glucose elevation as a medication side effect, making drug-induced hyperglycemia one of the most common metabolic complications in pharmacotherapy. Corticosteroids raise glucose by increasing hepatic glucose output and reducing peripheral insulin sensitivity—steroid-induced diabetes affects 15–30% of long-term users. Atypical antipsychotics (particularly olanzapine and clozapine) cause insulin resistance through weight gain and direct effects on insulin signaling in 40–60% of patients. Even common medications like thiazide diuretics and beta-blockers can raise fasting glucose by 5–10 mg/dL, potentially tipping someone from optimal into the concerning 90s range. Monitoring fasting glucose before and after starting any of these medication classes catches drug-induced metabolic disruption before it becomes irreversible.